2012 and beyond: potential for the start of a second pre-antibiotic era?

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

(2012) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of  -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii

(2012) P. G. Higgins et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

(2011) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efforts to Support the Development of Fusidic Acid in the United States

(2011) P. Fernandes et al.   CLINICAL INFECTIOUS DISEASES

The global need for effective antibiotics—A summary of plenary presentations

(2011) Gunnar Alvan et al.   DRUG RESISTANCE UPDATES

The global need for effective antibiotics—Moving towards concerted action

(2011) Otto Cars et al.   DRUG RESISTANCE UPDATES

Emergence and spread ofcfr-mediated multiresistance in staphylococci: an interdisciplinary challenge

(2011) Wolfgang Witte et al.   Future Microbiology

Effective antibacterials: at what cost? The economics of antibacterial resistance and its control

(2011) A. R. White et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Regulatory opportunities to encourage technology solutions to antibacterial drug resistance

(2011) R. Finch et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales

(2011) S. A. Chisholm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

(2011) I. Rodriguez-Avial et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study

(2011) R. N. Jones et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The urgent need for new antibacterial agents

(2011) R. Wise et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Discovery research: the scientific challenge of finding new antibiotics

(2011) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Microfossils of sulphur-metabolizing cells in 3.4-billion-year-old rocks of Western Australia

(2011) David Wacey et al.   Nature Geoscience

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

(2010) L. Saravolatz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections

(2010) P. Prokocimer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill Assay

(2010) G. Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli

(2010) M. G. P. Page et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Polymyxins and their novel derivatives

(2010) Martti Vaara   CURRENT OPINION IN MICROBIOLOGY

Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides

(2010) Y. Zhou et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Antibacterial oxazolidinones: emerging structure–toxicity relationships

(2010) Adam R Renslo   Expert Review of Anti-Infective Therapy

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)

(2010) David J. Farrell et al.   JOURNAL OF INFECTION

Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies

(2009) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

(2009) C. C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains

(2009) C. Juan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

(2008) I. A. Critchley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY